NCT05621655: Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
- State
- Under way
- Phase
- Phase 2
- People
- 1,512 taking part
- Started
- 8 Jan 2023
- Primary completion
- 29 Apr 2023
- Arms
- High dose in toddlers (7-71 months old, 3 doses), High dose in toddlers (7-71 months old, 2 doses), High dose in infants (6-12 weeks of age, 3 doses at 4-week intervals), High dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)
- Results
- None posted
- 18 Nov 2022: Trial registered
- 8 Jan 2023: Trial started